Immunohistochemistry has shown that treatment with trastuzumab induces dynamic changes in the tumor vasculature; in the acute state (14 days), trastuzumab treatment demonstrated CD31-positive blood vessels increase, whereas in the long-term (after 28 days) CD31-positive blood vessels decrease HER2-amplified xenografts [16]. Here, ERBB2 is linked to neoplasm.